Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels.
Lyphochek Benzo/TCA Control Set B is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and antidepressant drugs.
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis.
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing.
Medicine Products:(Date:7/25/2008)...es lung function, increases asthma risk, studies f...ews) -- A clean, fresh-smelling home may actually ...cleaning and air freshening products you use. ,...g products or air fresheners that contain a certai...lorobenzene (1,4 DCB), can reduce lung function by...
(Date:7/25/2008)...umers tips and encourages them to, ,Speak Up,(TM)...ly 25 /PRNewswire-USNewswire/ -- The Pennsylvania,...Patient Safety Day" which,is a national effort to ...te fully in their healthcare by asking questions a...y or illness., "We understand the important role ...
(Date:7/25/2008)...Fourth Annual Physician On-Call Pay ...swire/ -- Sullivan, Cotter and Associates, Inc.,ha...on-call pay rates and,practices, the 2008 Physicia...th data from 132 healthcare organizations nationwi...ates paid for 33 physician specialty areas along,w...
(Date:7/25/2008)...icant Improvements in Members, Health, ATLANTA, J...n health,care quality management solutions for hea...tered into a long-term agreement with Wellmark, In... on Quality(SM) Incent and,Reward Best Practices i...imary care clinicians to promote improved quality ...
Breaking Medicine News(10 mins):Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3(Date:7/22/2008)...wo Regimens Including Lantus(R) and Apidra(R) Resu... with Type 2 Diabetes, Whatever the Algorithm ....J., July 22 /- Results from the "Adj...Simple Algorithm to Carbohydrate,Counting for Adju...published in the American Diabetes Association,s (...
(Date:7/22/2008)...SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire/ ...t it has completed patient enrollment,in its Phase...bility and,ammonia scavenging effects of HPN-100 (...henylbutyrate) in patients with urea cycle disorde...esults in the fourth quarter,of this year., (Logo...
(Date:7/22/2008)... Developed and Validated by Columbia University Me...Proprietary MicroRNA Technology, The Test Differ... Lung Cancer (NSCLC), Classifying Squamous-Cell C... Percent and Specificity of 90 Percent,This is the...s, Sensitivity as Biomarkers for Accurate...
(Date:7/22/2008)...SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-Firs...nnounced it has successfully completed the,enrollm...olled hypertension,in two clinical pharmacology st...y announced timelines. These trials are designed t..., in comparison to ibuprofen and,naproxen, using t...
Breaking Medicine Technology:Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 1Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 2Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 3Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 4Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 5Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 6Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 7Alexzas AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2a Trial Meets Primary Endpoint of 2 Hour Pain Relief in Patients with Migraine Headache 1451 8The Quigley Corporation Announces Sale of Its Health and Wellness Segment 13232 1The Quigley Corporation Announces Sale of Its Health and Wellness Segment 13232 2The Quigley Corporation Announces Sale of Its Health and Wellness Segment 13232 3Up for Debate This Week 3A National Service Mental Health Coverage and Consumer Product Safety 13227 1Up for Debate This Week 3A National Service Mental Health Coverage and Consumer Product Safety 13227 2Up for Debate This Week 3A National Service Mental Health Coverage and Consumer Product Safety 13227 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3644 1NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3644 2NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3644 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3644 4NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3644 5...grenox® (Asasantin® Retard) considered by ..., ,INGELHEIM, Germany, 31 May 2007 - New data pre...e in Glasgow confirm that therapy,with dipyridamol...,is marketed as Aggrenox® or Asasantin® Re...vascular events in patients who had,a TIA or minor...
...NIPEG, Manitoba - (May 31, 2007) Medicure Inc. (TS...maceutical company,today announced that the resul...n a peer reviewed article in the June edition of T... published by the,American Association of Thoracic...xal-5-phosphate (MC-1) in,patients undergoing high...
Other Medicine Technology:New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 2New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 3New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 4Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal 2Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal 3Medicure's MEND-CABG Trial Results Published in Peer Reviewed,Journal 4